Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment

Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs

(2017) Parham Jabbarzadeh Kaboli et al.   Recent Patents on Anti-Cancer Drug Discovery

Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis

(2016) Ts-Ting Lin et al.   JOURNAL OF CONTROLLED RELEASE

Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells

(2015) Inna Zubrilov et al.   CANCER LETTERS

Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

(2015) Igor Puzanov et al.   EUROPEAN JOURNAL OF CANCER

MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment

(2015) Parham Jabbarzadeh Kaboli et al.   PHARMACOLOGICAL RESEARCH

Binding interaction of sorafenib with bovine serum albumin: Spectroscopic methodologies and molecular docking

(2015) Jie-Hua Shi et al.   SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Ligand efficiency indices as a navigation tool in the transthyretin protein chemico-biological space to find new amyloidogenic inhibitors

(2015) D. Blasi et al.   ACTA CRYSTALLOGRAPHICA SECTION A

Berberine Up-Regulates Hepatic Low-Density Lipoprotein Receptor through Ras-Independent but AMP-Activated Protein Kinase-Dependent Raf-1 Activation

(2014) Zheng Li et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer

(2014) Parham Jabbarzadeh Kaboli et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Alternative variables in drug discovery: promises and challenges

(2014) Cele Abad-Zapatero et al.   Future Medicinal Chemistry

Testing and validation of the Automated Topology Builder (ATB) version 2.0: prediction of hydration free enthalpies

(2014) Katarzyna B. Koziara et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Automatic GROMACS Topology Generation and Comparisons of Force Fields for Solvation Free Energy Calculations

(2014) Magnus Lundborg et al.   JOURNAL OF PHYSICAL CHEMISTRY B

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib

(2014) Sara D. Robinson et al.   LUNG CANCER

Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma

(2014) WENMIN HOU et al.   Oncology Letters

The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy

(2014) Chung-Pu Wu et al.   Acta Pharmaceutica Sinica B

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

(2013) Kamal S. Saini et al.   CANCER TREATMENT REVIEWS

Discovery, synthesis and biological evaluation of cycloprotoberberine derivatives as potential antitumor agents

(2013) Yang-Biao Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations

(2012) Napat Songtawee et al.   JOURNAL OF MOLECULAR MODELING

Correction for Wang et al., Ligand binding to protein-binding pockets with wet and dry regions

(2012)   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells

(2011) Ana Burgeiro et al.   ANTI-CANCER DRUGS

MEK1/2 dual-specificity protein kinases: Structure and regulation

(2011) Robert Roskoski   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0

(2011) Alpeshkumar K. Malde et al.   Journal of Chemical Theory and Computation

Ligand Efficiency Indices (LEIs): More than a Simple Efficiency Yardstick

(2011) Cele Abad-Zapatero et al.   Molecular Informatics

RAF protein-serine/threonine kinases: Structure and regulation

(2010) Robert Roskoski   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Non-oxime inhibitors of B-RafV600E kinase

(2010) Li Ren et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Non-oxime pyrazole based inhibitors of B-Raf kinase

(2010) Bradley J. Newhouse et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Cytotoxicity of berberine on human cervical carcinoma HeLa cells through mitochondria, death receptor and MAPK pathways, and in-silico drug-target prediction

(2010) Binan Lu et al.   TOXICOLOGY IN VITRO

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA